Intermediate dry age-related macular degeneration

Allegro successfully completed a Phase 2a trial of patients with intermediate non-exudative AMD (intermediate dry AMD). Full results are anticipated in the second half of 2019. View study on ClinicalTrials.gov.

Diabetic macular edema

Risuteganib met its primary endpoints in two Phase 2b trials. Allegro is now preparing for two Phase 3 trials in subjects with DME. Read more about the completed Phase 2b studies. View study on ClinicalTrials.gov.

Dry eye disease

ALG-1007 demonstrated promising results in an ex-U.S. proof-of-concept clinical trial, in which it showed efficacy, a significant dose response curve, and that it was well-tolerated with no adverse events. A second and larger ex-U.S. Phase 2 clinical trial is underway with results anticipated in the second half of 2019.